Glioblastoma multiforme is the most lethal intrinsic brain tumor. Even with the existing
treatment regimen of surgery, radiation, and chemotherapy, the median survival time is only …

Brain tumor accounts for about 1.6% of incidence and 2.5% of mortality of all tumors, and the
median survival for brain tumor patients is only about 20 months. The treatment for brain …

Many drugs show promising results in laboratory research but eventually fail clinical trials.
We hypothesize that one main reason for this translational gap is that current cancer models …

At the moment, anaplastic changes within the brain are challenging due to the complexity of
neural tissue, leading to the inefficiency of therapeutic protocols. The existence of a cellular …

Abstract Temozolomide (TMZ), an imidazotetrazine, is a second-generation DNA alkylating
agent used as a first-line treatment of glioblastoma multiforme (GBM). It was approved by …

Glioblastoma multiforme (GBM) is the most common primary brain cancer. GBM has
aggressive development, and the pharmacological treatment remains a challenge due to …

The tumor immune microenvironment significantly affects tumor progression, metastasis,
and clinical therapy. Its basic cell components include tumor-associated endothelial cells …

The complexity and diversity of the biochemical processes that occur during tumorigenesis
and metastasis are frequently over-simplified in the traditional in vitro cell cultures. Two …

Glioblastoma is the most common and lethal brain tumor in adults. The incorporation of
temozolomide (TMZ) into the standard treatment has increased the overall survival rate of …

A brain tumor is an uncontrolled cell proliferation, a mass of tissue composed of cells that
grow and divide abnormally and appear to be uncontrollable by the processes that normally …